<DOC>
	<DOCNO>NCT02324049</DOCNO>
	<brief_summary>To evaluate safety tolerability intravenous ( IV ) administration SBC 103 subject mucopolysaccharidosis III , type B ( MPS IIIB , Sanfilippo B ) evaluable sign symptom developmental delay .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics/Efficacy SBC-103 MPS IIIB</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Key Patient great equal 2 year age less 12 year age time informed consent . Definitive diagnosis MPS IIIB . Documented developmental delay Key Received treatment gene therapy time Previous hematopoietic stem cell bone marrow transplant . Has internal nonremovable external metal item may present safety risk study assessment utilize magnetic field , medical condition circumstance MRI contraindicate accord local institutional policy . Known hypersensitivity egg .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MPS IIIB</keyword>
	<keyword>Mucopolysaccharidosis</keyword>
	<keyword>Mucopolysaccharidosis type IIIB</keyword>
	<keyword>Sanfilippo Syndrome</keyword>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Carbohydrate Metabolism , Inborn Errors</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Lysosomal Storage Diseases</keyword>
	<keyword>Mucinoses</keyword>
	<keyword>Mucopolysaccharidoses</keyword>
	<keyword>Pathologic Processes</keyword>
</DOC>